BioSpace News Archive

Zeposia offers relapsing remitting multiple sclerosis (RRMS) patients with active disease in the European Union a new oral option to help address the disease’s hallmark relapses and brain lesions

Deciphera Pharmaceuticals, Inc., a commercial biopharmaceutical company addressing key mechanisms of tumor drug resistance, announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies 2020 Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET.

Clinical Data Offer Meaningful Diagnostic Information for Patients in the Lung Cancer Continuum of Care

PROCEPT BioRobotics Corporation, a surgical robotics company developing intelligent solutions to transform the field of urology, has announced that results of the WATER II study demonstrate its Aquablation® therapy is safe and durable in large prostates at two years.

Jennewein Biotechnologie GmbH announces the publication of the latest results from its norovirus research program in the Journal of Biotechnology.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Adriana Cabré, MBA, as Vice President of Human Resources. “We are pleased to welcome Adriana to the executive team to lead our Human Resource function,” said Scott Struthers, Ph.D., Founder

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today provided an update on the preclinical results f

After almost 10 years of service as the CEO of Tegra Medical and as Head of the Medical division within the SFS Group, J. Mark King has decided to retire as of August 1, 2020 . The Board of Directors and the Group Executive Board thank J. Mark King for his many years of service, his contribution to the development of Tegra Medical

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, announced the appointment of William Delaney, PhD as Chief Scientific Officer, Virology, replacing Richard Colonno, PhD, who will retire and transition from this role on June 1, 2020.

Nascent Biotech, Inc is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma, the deadliest form of brain cancer.